Orieta Celiku

Dr. Orieta Celiku

orcid

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2019 in Cancer Research
Verified
Journal Article
Closed access
PDF file
JJJinkyu Jung
Jinkyu Jung
YZYing Zhang
Ying Zhang
OCOrieta Celiku
Orieta Celiku
WZWei Zhang
Wei Zhang
HSHua Song
Hua Song
DPDeric M. Park
Deric M. Park
Cancer cells rely on mitochondrial functions to regulate key survival and death signals. How cancer cells regulate mitochondrial autophagy (mitophagy) in the tumor microenvironment as well as utilize mitophagy as a survival signal is still not well understood. Here, we elucidate a key survival mechanism of mitochondrial NIX-mediated mitophagy within the hypoxic region of glioblastoma, the most malignant brain tumor. NIX was overexpressed in the pseudopalisading cells that envelop the hypoxic–necrotic regions, and mitochondrial NIX expression was robust in patient-derived glioblastoma tumor tissues and glioblastoma stem cells. NIX was required for hypoxia and oxidative stress–induced mitophagy through NFE2L2/NRF2 transactivation. Silencing NIX impaired mitochondrial reactive oxygen species clearance, cancer stem cell maintenance, and HIF/mTOR/RHEB signaling pathways under hypoxia, resulting in suppression of glioblastoma survival in vitro and in vivo. Clinical significance of these findings was validated by the compelling association between NIX expression and poor outcome for patients with glioblastoma. Taken together, our findings indicate that the NIX-mediated mitophagic pathway may represent a key therapeutic target for solid tumors, including glioblastoma. Significance: NIX-mediated mitophagy regulates tumor survival in the hypoxic niche of glioblastoma microenvironment, providing a potential therapeutic target for glioblastoma. Graphical http://cancerres.aacrjournals.org/content/canres/79/20/5218/F1.large.jpg. Graphical Abstract

1 May 2015 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
UMUday Bhanu Maachani
Uday Bhanu Maachani
TKTamalee Kramp
Tamalee Kramp
RHRyan Hanson
Ryan Hanson
SZShuping Zhao
Shuping Zhao
OCOrieta Celiku
Orieta Celiku
ATAnita Tandle
Anita Tandle
To ensure faithful chromosome segregation, cells use the spindle assembly checkpoint (SAC), which can be activated in aneuploid cancer cells. Targeting the components of SAC machinery required for the growth of aneuploid cells may offer a cancer cell–specific therapeutic approach. In this study, the effects of inhibiting Monopolar spindle 1, MPS1 (TTK), an essential SAC kinase, on the radiosensitization of glioblastoma (GBM) cells were analyzed. Clonogenic survival was used to determine the effects of the MPS1 inhibitor NMS-P715 on radiosensitivity in multiple model systems, including GBM cell lines, a normal astrocyte, and a normal fibroblast cell line. DNA double-strand breaks (DSB) were evaluated using γH2AX foci, and cell death was measured by mitotic catastrophe evaluation. Transcriptome analysis was performed via unbiased microarray expression profiling. Tumor xenografts grown from GBM cells were used in tumor growth delay studies. Inhibition of MPS1 activity resulted in reduced GBM cell proliferation. Furthermore, NMS-P715 enhanced the radiosensitivity of GBM cells by decreased repair of DSBs and induction of postradiation mitotic catastrophe. NMS-P715 in combination with fractionated doses of radiation significantly enhanced the tumor growth delay. Molecular profiling of MPS1-silenced GBM cells showed an altered expression of transcripts associated with DNA damage, repair, and replication, including the DNA-dependent protein kinase (PRKDC/DNAPK). Next, inhibition of MPS1 blocked two important DNA repair pathways. In conclusion, these results not only highlight a role for MPS1 kinase in DNA repair and as prognostic marker but also indicate it as a viable option in glioblastoma therapy. Implications: Inhibition of MPS1 kinase in combination with radiation represents a promising new approach for glioblastoma and for other cancer therapies. Mol Cancer Res; 13(5); 852–62. ©2015 AACR.

27 January 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ALAdrian Lita
Adrian Lita
APArtem Pliss
Artem Pliss
Andrey KuzminAndrey Kuzmin
Andrey Kuzmin
TYTomohiro Yamasaki
Tomohiro Yamasaki
LZLumin Zhang
Lumin Zhang
MLMioara Larion
Mioara Larion
Infiltrating gliomas are devastating and incurable tumors. Amongst all gliomas, those harboring a mutation in isocitrate dehydrogenase 1 mutation (IDH1mut) acquire a different tumor biology and clinical manifestation from those that are IDH1WT. Understanding the unique metabolic profile reprogrammed by IDH1 mutation has the potential to identify new molecular targets for glioma therapy. Herein, we uncover increased monounsaturated fatty acids (MUFA) and their phospholipids in endoplasmic reticulum (ER), generated by IDH1 mutation, that are responsible for Golgi and ER dilation. We demonstrate a direct link between the IDH1 mutation and this organelle morphology via D-2HG-induced stearyl-CoA desaturase (SCD) overexpression, the rate-limiting enzyme in MUFA biosynthesis. Inhibition of IDH1 mutation or SCD silencing restores ER and Golgi morphology, while D-2HG and oleic acid induces morphological defects in these organelles. Moreover, addition of oleic acid, which tilts the balance towards elevated levels of MUFA, produces IDH1mut-specific cellular apoptosis. Collectively, these results suggest that IDH1mut-induced SCD overexpression can rearrange the distribution of lipids in the organelles of glioma cells, providing new insight into the link between lipid metabolism and organelle morphology in these cells, with potential and unique therapeutic implications.

1 September 2009
Verified
Conference Paper
Closed access
DGDavid Garlan
David Garlan
JBJeffrey M. Barnes
Jeffrey M. Barnes
BSBradley Schmerl
Bradley Schmerl
OCOrieta Celiku
Orieta Celiku
As new market opportunities, technologies, platforms, and frameworks become available, systems require large-scale and systematic architectural restructuring to accommodate them. Today's architects have few tools and techniques to help them plan this architecture evolution. In particular, they have little assistance in planning alternative evolution paths, trading off various aspects of the different paths, or knowing best practices for particular domains. In this paper we describe an approach for assisting architects in developing and reasoning about architectural evolution paths. The key insight of our approach is that, architecturally, many system evolutions follow certain common patterns - or evolution styles. We define what we mean by an evolution style, and show how it can be used to provide automated assistance for expressing architectural evolution, and for reasoning about both the correctness and quality of evolution paths.

10 July 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OCOrieta Celiku
Orieta Celiku
SJSeth Johnson
Seth Johnson
SZShuping Zhao
Shuping Zhao
KCKevin Camphausen
Kevin Camphausen
USUma Shankavaram
Uma Shankavaram
Validation of clinical biomarkers and response to therapy is a challenging topic in cancer research. An important source of information for virtual validation is the datasets generated from multi-center cancer research projects such as The Cancer Genome Atlas project (TCGA). These data enable investigation of genetic and epigenetic changes responsible for cancer onset and progression, response to cancer therapies, and discovery of the molecular profiles of various cancers. However, these analyses often require bulk download of data and substantial bioinformatics expertise, which can be intimidating for investigators. Here, we report on the development of a new resource available to scientists: a data base called Glioblastoma Bio Discovery Portal (GBM-BioDP). GBM-BioDP is a free web-accessible resource that hosts a subset of the glioblastoma TCGA data and enables an intuitive query and interactive display of the resultant data. This resource provides visualization tools for the exploration of gene, miRNA, and protein expression, differential expression within the subtypes of GBM, and potential associations with clinical outcome, which are useful for virtual biological validation. The tool may also enable generation of hypotheses on how therapies impact GBM molecular profiles, which can help in personalization of treatment for optimal outcome. The resource can be accessed freely at http://gbm-biodp.nci.nih.gov (a tutorial is included).

19 January 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
DKDiane M. Kambach
Diane M. Kambach
AHAlan S. Halim
Alan S. Halim
ACA. Gesine Cauer
A. Gesine Cauer
QSQian Sun
Qian Sun
CTCarlos A. Tristan
Carlos A. Tristan
JSJayne Stommel
Jayne Stommel
Disabled cell density sensing leads to dysregulated cholesterol synthesis in glioblastoma